Aripiprazole: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
VisualWikitext
m (add missing word)
m (Text replacement - "|issue=" to " | issue = ")
 
(87 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{stub}}
{{NeedsImage}}
'''Aripiprazole''', which is also sold under the brand names '''abilify''' and '''aripiprazol''', is an atypical [[Antipsychotic|antipsychotic drug]] used for a number of different conditions including:
'''Aripiprazole''', which is also sold under the brand names '''Abilify''' and '''Aripiprazol''', is an atypical [[Antipsychotic|antipsychotic drug]] and [[:Category:Anti-inflammatories |anti-inflammatory drug]] used for a number of different conditions including:
*agitated state
*Agitated state
*Autism
*Autism
*Bipolar disorder (manic depression)
*Bipolar disorder (manic depression)
Line 7: Line 7:
*Obsessive Compulsive Disorder  
*Obsessive Compulsive Disorder  
*[[Post-traumatic stress disorder]] (PTSD)
*[[Post-traumatic stress disorder]] (PTSD)
*Schizophrenia and Schizoaffective Disorder, and
*Schizophrenia and Schizoaffective Disorder  
*Tourette's syndrome<ref name="drugscom">https://www.drugs.com/international/aripiprazole.html</ref >
*Tourette's syndrome<ref name="drugscom">{{Cite web | url = https://www.drugs.com/international/aripiprazole.html | title = Aripiprazole | website = Drugs.com|language=en | access-date = 2020-10-04}}</ref>


==Theory==
==Theory==
One hypothesized theory of aripiprazole’s mode of action is that it may work as a biofilm disruptor<ref>{{Cite journal | last = Rajasekharan | first = Satish Kumar | last2 = Lee | first2 = Jin-Hyung | last3 = Lee | first3 = Jintae | date = Oct 2019 | title = Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans |url =https://pubmed.ncbi.nlm.nih.gov/31173863/ | journal = International Journal of Antimicrobial Agents | volume = 54 | issue = 4 | pages = 518–523|doi=10.1016/j.ijantimicag.2019.05.016|issn=1872-7913|pmid=31173863|pmc=|quote=|via=}}</ref> and affect the gut-brain axis that way.


==Evidence==
==Evidence==
Line 19: Line 20:


==Costs and availability==
==Costs and availability==
Aripiprazole is not approved for use in [[ME/CFS]], and no clinical trials have been conducted with ME/CFS patients. Aripiprazole is approved by the FDA, by the European Medicines Agency (EMA) and UK's Medicines Agency for schizophrenia, manic episodes in bipolar I disorder, and for irritability associated with autistic disorders, and other uses.<ref name="Abilify">{{Cite web | url = https://www.medicines.org.uk/emc/product/7148/smpc | access-date = 2021-11-03 | title = Abilify 5mg tablets | website = Electronic Medicines Compendium}}</ref> Aripiprazole is sometimes used as an add-on treatment together with an [[antidepressant]].<ref name="FDAleaflet" />
Aripiprazole, including the brand name Abilify, is an inexpensive perscription-only drug, available as an oral solution, tablet, disolvable powder, and as a powder for injections.<ref name="FDAleaflet">{{Cite web  | website = Food and Drug Administration | url =https://www.fda.gov/media/73102/download | title = Ability medication guide | date = | access-date = 2021-11-03}}</ref><ref name="medicinesUK">{{Cite web | url = https://www.medicines.org.uk/emc/search?q=Aripiprazole+ | title = Aripiprazole Search Results | last = | first = | author-link = | date = | website = Electronic Medicines Compendium| archive-url = | archive-date = |url-status = | access-date=2021-11-03}}</ref>
==Patient group statements==
*[https://meassociation.org.uk/2021/05/me-association-statement-aripiprazole-abilify-me-cfs/ ME Association statement on Aripiprazole (Abilify) for ME/CFS (2021)]
*[https://www.actionforme.org.uk/news/responding-to-questions-about-abilify/ Responding to questions about Ability] - Action for ME (2021)
*[https://anzmes.org.nz/what-is-me/frequently-asked-questions/ What is M.E.? | FAQ] - Australia and New Zealand ME Association (2021)
==Talks, presentations and videos ==
*[https://meassociation.org.uk/2021/10/iacfs-me-conference-dr-hector-bonilla-on-case-presentation-treating-me-cfs-with-aripiprazole/ Case Presentation: Treating ME/CFS with Aripiprazole. IACFS/ME Conference 2021] - Hector Bonilla
*2021, [https://med.stanford.edu/content/dam/sm/dbds/documents/data-studio/abstract.20201118.pdf The Impact of Aripiprazole on Chronic Fatigue Syndrome] - Hector Bonilla


==Notable studies ==
==Notable studies ==
* 2012, The role of Antipsychotics in the Management of Fibromyalgia<ref name="Calandre2012">https://link.springer.com/article/10.2165/11597130-000000000-00000</ref > - [https://link.springer.com/article/10.2165/11597130-000000000-00000 (Abstract)]
* 2012, The role of Antipsychotics in the Management of Fibromyalgia<ref name="Calandre2012">{{Cite journal | last = Calandre | first = Elena P. | last2 = Rico-Villademoros | first2 = Fernando | date = 2012-02-01 | title = The Role of Antipsychotics in the Management of Fibromyalgia | url = https://doi.org/10.2165/11597130-000000000-00000 | journal = CNS Drugs|language=en | volume = 26 | issue = 2 | pages = 135–153|doi=10.2165/11597130-000000000-00000|issn=1179-1934}}</ref> - [https://link.springer.com/article/10.2165/11597130-000000000-00000 (Abstract)]
* 2018, Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation<ref name="PMC5965391">{{Cite journal | last = Omori | first = Yuki | last2 = Kanbayashi | first2 = Takashi | last3 = Sagawa | first3 = Yohei | last4 = Imanishi | first4 = Aya | last5 = Tsutsui | first5 = Ko | last6 = Takahashi | first6 = Yuya | last7 = Takeshima | first7 = Masahiro | last8 = Takaki | first8 = Manabu | last9 = Nishino | first9 = Seiji | date = 2018-05-18 | title = Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation | url =https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965391/ | journal = Neuropsychiatric Disease and Treatment | volume = 14 | pages = 1281–1286|doi=10.2147/NDT.S158865|issn=1176-6328|pmc=5965391|pmid=29849459}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965391/ (Full text)]
* 2019, Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans<ref>{{Cite journal | last = Rajasekharan | first = Satish Kumar | last2 = Lee | first2 = Jin-Hyung | last3 = Lee | first3 = Jintae | date = Oct 2019 | title = Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans |url =https://pubmed.ncbi.nlm.nih.gov/31173863/ | journal = International Journal of Antimicrobial Agents | volume = 54 | issue = 4 | pages = 518–523|doi=10.1016/j.ijantimicag.2019.05.016|issn=1872-7913|pmid=31173863}}</ref>
* 2021, Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole<ref name="Crosby2021">{{Cite journal | last = Crosby | first = L.D. |  author-link = Laurel Crosby | last2 = Kalanidhi | first2 = S. | author-link2 = | last3 = Bonilla | first3 = A. |  author-link3 = | last4 = Subramanian | first4 = A. |  author-link4 = | last5 = Ballon | first5 = J. S. |  author-link5 = | last6 = Bonilla | first6 = H. |  author-link6 = Hector Bonilla | date = 2021-02-03 | title = Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole | url =https://doi.org/10.1186/s12967-021-02721-9 | journal = Journal of Translational Medicine|language=en | volume = 19 | issue = 1 | pages = 50|doi=10.1186/s12967-021-02721-9|issn=1479-5876|pmc=PMC7860172|pmid=33536023|access-date=|quote=|via=}}</ref> [https://doi.org/10.1186/s12967-021-02721-9 (Full text)]
::[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02875-6 correction]
*2021, Extremely Severe ME/CFS—A Personal Account <ref name="Dafoe2021">{{Cite journal | last = Dafoe | first = Whitney |  author-link = | date = May 2021 | title = Extremely Severe ME/CFS—A Personal Account | url = https://www.mdpi.com/2227-9032/9/5/504 | journal = Healthcare|language=en | volume = 9 | issue = 5 | pages = 504|doi=10.3390/healthcare9050504|pmc=|pmid=|access-date=|quote=|via=}}</ref> [https://www.mdpi.com/1088982 (Full text)]
 
==Articles and blogs ==
*2021, [https://www.healthrising.org/blog/2021/03/09/abilify-chronic-fatigue-syndrome-promise/ Abilify shows promise in retrospective Chronic Fatigue Syndrome (ME/CFS) study] - Cort Johnson, Health Rising
 
== Blogs ==
* Oct 2020,[https://www.healthrising.org/blog/2020/10/03/celebrating-whitney-dafoe-and-his-awakening-on-his-37th-birthday/ Celebrating Whitney's Dafoe and his "Awakening" on his 37th birthday] - Health Rising


==See also==
==See also==
Line 27: Line 51:
*[[Fibromyalgia drugs]]
*[[Fibromyalgia drugs]]
*[[Myalgic encephalomyelitis]]
*[[Myalgic encephalomyelitis]]
*[[Whitney Dafoe]]


==Learn more==
==Learn more==
*[https://www.drugs.com/international/aripiprazole.html Aripiprazole]
*[https://www.drugs.com/international/aripiprazole.html Aripiprazole] - Drugs.com
==References ==
==References ==
{{Reflist}}
{{Reflist}}
Line 35: Line 60:
[[Category:Antipsychotics]]
[[Category:Antipsychotics]]
[[Category:Potential treatments]]
[[Category:Potential treatments]]
[[Category:Anti-inflammatories]]

Latest revision as of 15:02, April 3, 2023

Aripiprazole, which is also sold under the brand names Abilify and Aripiprazol, is an atypical antipsychotic drug and anti-inflammatory drug used for a number of different conditions including:

Theory[edit | edit source]

One hypothesized theory of aripiprazole’s mode of action is that it may work as a biofilm disruptor[2] and affect the gut-brain axis that way.

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Aripiprazole is not approved for use in ME/CFS, and no clinical trials have been conducted with ME/CFS patients. Aripiprazole is approved by the FDA, by the European Medicines Agency (EMA) and UK's Medicines Agency for schizophrenia, manic episodes in bipolar I disorder, and for irritability associated with autistic disorders, and other uses.[3] Aripiprazole is sometimes used as an add-on treatment together with an antidepressant.[4]

Aripiprazole, including the brand name Abilify, is an inexpensive perscription-only drug, available as an oral solution, tablet, disolvable powder, and as a powder for injections.[4][5]

Patient group statements[edit | edit source]

Talks, presentations and videos[edit | edit source]

Notable studies[edit | edit source]

  • 2012, The role of Antipsychotics in the Management of Fibromyalgia[6] - (Abstract)
  • 2018, Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation[7] (Full text)
  • 2019, Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans[8]
  • 2021, Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole[9] (Full text)
correction

Articles and blogs[edit | edit source]

Blogs[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ "Aripiprazole". Drugs.com. Retrieved October 4, 2020.
  2. ↑ Rajasekharan, Satish Kumar; Lee, Jin-Hyung; Lee, Jintae (October 2019). "Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans". International Journal of Antimicrobial Agents. 54 (4): 518–523. doi:10.1016/j.ijantimicag.2019.05.016. ISSN 1872-7913. PMID 31173863.
  3. ↑ "Abilify 5mg tablets". Electronic Medicines Compendium. Retrieved November 3, 2021.
  4. ↑ 4.0 4.1 "Ability medication guide". Food and Drug Administration. Retrieved November 3, 2021.
  5. ↑ "Aripiprazole Search Results". Electronic Medicines Compendium. Retrieved November 3, 2021.
  6. ↑ Calandre, Elena P.; Rico-Villademoros, Fernando (February 1, 2012). "The Role of Antipsychotics in the Management of Fibromyalgia". CNS Drugs. 26 (2): 135–153. doi:10.2165/11597130-000000000-00000. ISSN 1179-1934.
  7. ↑ Omori, Yuki; Kanbayashi, Takashi; Sagawa, Yohei; Imanishi, Aya; Tsutsui, Ko; Takahashi, Yuya; Takeshima, Masahiro; Takaki, Manabu; Nishino, Seiji (May 18, 2018). "Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation". Neuropsychiatric Disease and Treatment. 14: 1281–1286. doi:10.2147/NDT.S158865. ISSN 1176-6328. PMC 5965391. PMID 29849459.
  8. ↑ Rajasekharan, Satish Kumar; Lee, Jin-Hyung; Lee, Jintae (October 2019). "Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans". International Journal of Antimicrobial Agents. 54 (4): 518–523. doi:10.1016/j.ijantimicag.2019.05.016. ISSN 1872-7913. PMID 31173863.
  9. ↑ Crosby, L.D.; Kalanidhi, S.; Bonilla, A.; Subramanian, A.; Ballon, J. S.; Bonilla, H. (February 3, 2021). "Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole". Journal of Translational Medicine. 19 (1): 50. doi:10.1186/s12967-021-02721-9. ISSN 1479-5876. PMC 7860172. PMID 33536023.
  10. ↑ Dafoe, Whitney (May 2021). "Extremely Severe ME/CFS—A Personal Account". Healthcare. 9 (5): 504. doi:10.3390/healthcare9050504.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.

Retrieved from "https://me-pedia.org/w/index.php?title=Aripiprazole&oldid=240176"